Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series. (PubMed, Front Psychiatry) - Sep 13, 2026 - "We conducted a longitudinal retrospective case series of three biomarker-positive individuals from the Alzheimer's Disease Neuroimaging Initiative who received lecanemab or donanemab. Conventional global screening tools may underestimate early decline and affect treatment eligibility decisions. Although not generalizable, these observations underscore the need for larger real-world studies characterizing clinical trajectories following anti-amyloid therapy."
Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
|
|
Darlingtina Esiaka; Jayoung Han; Olufunmilola Abraham; Yuan Fang
|